TrumpRx now prioritizes generics that comprise ~90% of US prescriptions, shifting from a brand-heavy list toward medications more likely to affect broad population-level out-of-pocket spending.
Jerry A. Krishnan, MD, PhD, discusses NIH RECOVER findings on long COVID, pulmonary complications, and immune dysfunction at ATS 2026. In this Q&A, Krishnan highlights how long COVID, heterogeneity, ...
Parametric survival modeling from FIBRONEER-IPF projected median survival of 3.7 years on placebo versus 5.8 and 9.1 years with nerandomilast 9 mg and 18 mg monotherapy. Background nintedanib ...
Implementing Early Detection in CRM Syndrome,’ the expert nephrologist explored the following questions: What role do ...
FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...
Efficacy and Safety of Sotatercept in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Connective Tissue ...
Manhattan cordon pricing south of 60th Street reduced traffic volumes and increased bus use, with hypothesized local/regional ...
Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian ...
PASSAGE study data showed tezepelumab improved asthma outcomes across diverse, underrepresented patient populations. Data presented at the American Thoracic Society 2026 International Conference in ...
Inverse-probability reweighting of NHANES 1988–1991 to 2021–2023 demographics projected 5.3 million US adults with ASCVD and ...
ATS 2026 findings highlighted bleeding risks and hemodynamic responses with sotatercept in CTD-associated pulmonary arterial hypertension (PAH). In an interview with The American Journal of Managed ...
Communication gaps persisted despite shared decision-making norms, with limited patient-perceived comprehension and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results